FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesDave Mitchell Webinar Series
Topics: Communication, Leadership, Personal Development, Team Building
Webinar
Members
Nat'l Coronavirus Response - Road Map to Reopening
Topics: Health Care, Strategic Planning
Report
Free
Acting Decisively
Members
